Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
9MW2821 Plus Toripalimab in First-line Advanced Urothelial Cancer
NCT06592326Phase 3Recruiting
- Sponsor
- Mabwell
- Start
- Aug 2024
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bulumtatug fuvedotin in urothelial carcinoma (UC), sponsored by Mabwell. Primary endpoints: Blind Independent Central Review Progression-Free Survival up to 50 months and Overall Survival up to 50 months. Started Aug 2024; status: recruiting.
02
Drugs
bulumtatug fuvedotin
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT06592326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06592326.